Article
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
1 Jan 2018
Abstract excerpt
Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and...
Topics
Join the communities discussing this publication.